ARCHIVES

Bayer’s HER-2/neu Blood Test Cleared By FDA For Marketing.

This article is from The Cancer Letter archive.

Vol. 26 No. 46 | December 15, 2000

Download PDF Visit The Full Archive

Related Articles

Drug Development: FDA Grants Breakthrough Therapy Designation To CTL019 in ALL

June 11, 2014

NCI plans 11-16 percent budget cuts in new grants to maintain R01 payline at 20th percentile.

November 28, 2003

NCI Sends A Second Letter To Groups About Carboplatin

October 22, 2010

Immunoassays For Isoenzymes

April 15, 1983

New NCAB Weak In Grant Reviews, Confused By Issues

December 10, 1982

GAO: FDA Data On Drug Shortages Inadequate

February 21, 2014